top of page
The Sound of Evolution
Tocilizumab
Mechanism of action:
Tocilizumab is a humanized monoclonal antibody against the interleukin-6 receptor. Tocilizumab binds both the membrane-bound IL-6 receptor and the soluble IL-6 receptor, preventing IL-6 from binding to them and thereby interrupting downstream signaling pathways, including pro-inflammatory cascades such as JAK-STAT and MAPK.
Reference(s):
1. Cellina M et al. (2020). Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab. Diagn Interv Imaging.
2. Ding C et al. (2003). Technology evaluation: MRA, Chugai. Curr Opin Mol Ther.
3. Keizer RJ et al. (2010). Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet.
bottom of page